Highlights
- September-quarter FY27 net sales contracts totalled USD 25.1 million.
- Contracted Revenue reached USD 143.7 million at 30 September 2026.
- FY26 revenue increased 15% to USD 60.9 million.
- The active trial portfolio rose from 110 to 171 during FY26.
Cogstate Limited (ASX:CGS) provides cognitive assessments, central rating services and clinical-trial endpoint quality solutions to pharmaceutical research sponsors. Its financial year ended June 2026 brought higher sales contracts and trial activity. The subsequent September 2026 Business update showed a larger contracted revenue base, although the timing of clinical trial work remains important in determining when signed contracts translate into recognised revenue.
FY26 Revenue and Profit Progress
Revenue increased to USD 60.9 million in FY26 from USD 53.1 million, a 15% gain. Clinical Trials revenue was USD 58.4 million, compared with USD 50.6 million, while Healthcare revenue remained near USD 2.5 million. Earnings before interest, tax, Depreciation and Amortisation (EBITDA) rose to USD 18.3 million from USD 16.0 million.
Net profit after tax reached USD 11.9 million, up from USD 10.1 million. Gross Profit was USD 35.4 million, although the gross Margin declined from 61% to 58%. This combination of higher absolute profit and a lower gross margin illustrates why revenue growth should be considered alongside the mix and cost of services delivered.
Sales Contracts and September Revenue Coverage
During the September quarter of FY27, Cogstate executed USD 25.1 million of net sales contracts, compared with USD 21.4 million in the September 2025 quarter. Contracted future revenue, including revenue recognised during the quarter, reached USD 143.7 million at 30 September 2026, versus USD 101.8 million a year earlier, representing growth of 41%.
Of that amount, USD 56.8 million related to FY27, up from USD 48.3 million at 30 June 2026. Management said USD 8.4 million of newly signed September-quarter contracts contributed to FY27 contracted revenue. The value of work under contract does not equal revenue already earned: study timing, delivery progress and recognition conditions affect the conversion schedule.
Diversification Beyond Alzheimer’s Trials
Cogstate said five Phase 3 bipolar or depression studies across two customers accounted for more than 80% of September-quarter contract value. This concentration within one reporting period coexists with the company's longer-term move into broader central nervous system indications. During FY26, 77% of contract value originated outside Alzheimer's disease research.
Active clinical trials increased from 110 at 1 July 2025 to 171 at 30 June 2026, while 90 new trials started during FY26 compared with 35 a year earlier. More simultaneous studies can broaden revenue opportunities, but it also increases demands on clinical data quality, staffing and technology systems.
Technology Investment and Delivery Risks
Cogstate described plans to invest in artificial-intelligence-assisted rater Training and central monitoring, aiming to improve consistency and scalability across regulated trials. These initiatives remain investments and development plans, not evidence that labour costs have already fallen or that new software products have delivered revenue.
The group reported USD 34.8 million of cash at the FY26 year-end and no debt. Management expected revenue growth in FY27, conditional on sales execution and timing, while flagging a second-half weighting in annual performance. Variability in new trial awards, study delays and implementation costs could affect the earnings profile despite improved contracted revenue visibility.
Key Insights
Cogstate's growing clinical-trial portfolio and USD 143.7 million contracted revenue position provide a more substantial pipeline for future delivery. However, contracts are recognised as services are performed, and scaling trial operations while investing in technology remains an important commercial challenge.
_11_16_2026_11_23_12_237620.jpg)

_11_16_2026_07_52_44_870464.jpg)



Please wait processing your request...